ARTIFACT SHEET

Enter artifact number below. Artifact number is application number + artifact type code (see list below) + sequential letter (A, B, C ...). The first artifact folder for an artifact type receives the letter A, the second B, etc..
Examples: 59123456PA, 59123456PB, 59123456ZA, 59123456ZB

09693213BA

Indicate quantity of a single type of artifact received but not scanned. Create individual artifact folder/box and artifact number for each Artifact Type.

☐ CD(s) containing:
- computer program listing — ☐ Doc Code: Computer — Artifact Type Code: P
- pages of specification and/or sequence listing and/or table — ☐ Doc Code: Artifact — Artifact Type Code: S
- content unspecified or combined — ☐ Doc Code: Artifact — Artifact Type Code: U

☐ Stapled Set(s) Color Documents or B/W Photographs
Doc Code: Artifact Artifact Type Code: C

☐ Microfilm(s)
Doc Code: Artifact Artifact Type Code: F

☐ Video tape(s)
Doc Code: Artifact Artifact Type Code: V

☐ Model(s)
Doc Code: Artifact Artifact Type Code: M

☑ Bound Document(s)
Doc Code: Artifact Artifact Type Code: B

☐ Confidential Information Disclosure Statement or Other Documents marked Proprietary, Trade Secrets, Subject to Protective Order, Material Submitted under MPEP 724.02, etc.
Doc Code: Artifact Artifact Type Code X

☐ Other, description: _____
Doc Code: Artifact Artifact Type Code: Z

March 8, 2004

The United States of America

The Commissioner of Patents and Trademarks

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.

If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.

If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extension.

Bruce Lehman

Commissioner of Patents and Trademarks

Sandra L Morton

Attest

US005824796A

United States Patent [19]

Petrie et al.

[11] Patent Number: 5,824,796

[45] Date of Patent: Oct. 20, 1998

[54] **CROSS-LINKING OLIGONUCLEOTIDES**

[75] Inventors: **Charles R. Petrie**; **Rich B. Meyer**, both of Woodinville; **John C. Tabone**, Bothell, all of Wash.; **Gerald D. Hurst**, Iowa City, Iowa

[73] Assignee: **EPOCH Pharmaceuticals, Inc.**, Bothell, Wash.

[21] Appl. No.: **334,490**

[22] Filed: **Nov. 4, 1994**

Related U.S. Application Data

[63] Continuation of Ser. No. 49,807, Apr. 20, 1993, abandoned, which is a continuation of Ser. No. 353,857, May 18, 1989, abandoned, which is a continuation-in-part of Ser. No. 250,474, Sep. 28, 1988, abandoned.

[51] **Int. Cl.**[6] **C07H 19/04**; C07H 21/00; C07H 21/02; C07H 21/04

[52] **U.S. Cl.** **536/26.7**; 536/24.5

[58] **Field of Search** 536/26.1, 26.12, 536/26.13, 26.14, 26.8, 27.6, 27.81, 28.5, 28.54, 26.7, 24.5

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,598,807	8/1971	Nakayama et al.	
3,962,211	6/1976	Townsend et al.	
4,123,610	10/1978	Summerton et al.	536/28
4,582,789	4/1986	Sheldon et al.	
4,599,303	7/1986	Yabusaki et al.	
4,711,955	12/1987	Ward et al.	536/29
4,766,062	8/1988	Diamond et al.	435/6
4,795,700	1/1989	Dervan et al.	
4,837,311	6/1989	Tam et al.	
5,176,996	1/1993	Hogan et al.	436/6

FOREIGN PATENT DOCUMENTS

0021293	1/1981	European Pat. Off.	
0198207	10/1986	European Pat. Off.	C12Q 1/68
0227459	7/1987	European Pat. Off.	
0242264	10/1987	European Pat. Off.	C12P 19/34
0259186	3/1988	European Pat. Off.	
0266099	5/1988	European Pat. Off.	C07H 21/04
0267996	5/1988	European Pat. Off.	
0375406	6/1990	European Pat. Off.	C12N 15/10
3310337	9/1984	Germany	
6109797	11/1984	Japan	
84/03285	8/1984	WIPO	C07H 17/00
WO8502628	6/1985	WIPO	
WO8503075	7/1985	WIPO	
86/02929	5/1986	WIPO	C07H 15/12
86/04816	8/1986	WIPO	A61K 31/70
WO8707611	12/1987	WIPO	
88/10264	12/1988	WIPO	C07H 19/10
90/14353	11/1990	WIPO	C07H 21/00
90/15884	12/1990	WIPO	C12Q 1/68
91/18997	12/1991	WIPO	C12P 19/34
92/20698	11/1992	WIPO	C07H 21/04
93/03736	3/1993	WIPO	A61K 31/70

OTHER PUBLICATIONS

Hobbs, Frank W. Jr. *Org. Chem.*, (1989) 54:3420–3422.

Umlauf, Scott W. et al. *J. of Bio. Chem.* (1990) 265/28:16898–16912.

Register, James C. III et al. *J. of Bio. Chem.* (1987) 262/26:12812–12820.

Thoung, Nguyen Thanh et al. *Biochimie*, (1985) 67:673–684.

Chang, Susanne et al. *J. of Bio. Chem.* (1988) 263/20:15110–15117.

Knorre, D. G. et al. "complementarily addressed modification of double-stranded DNA in a triple-stranded complex" *Dokl. Akad. NAUK SSSR* (1988) 300/4:1006–9.

Petrie, Charles T. et al. *Bioconjugate Chemistry*, (1991) 2/6:441–446.

Sidwell, Robert W. et al. *Applied Microbiology*, (1968) 16/2:370–392.

Seela, Frank et al. *Nucleic Acids Research*, (1982) 10/4:1389–1397.

(List continued on next page.)

Primary Examiner—Gary L. Kunz
Attorney, Agent, or Firm—Klein & Szekeres, LLP

[57] **ABSTRACT**

This invention is directed to novel substituted nucleotide bases with a crosslinking arm which accomplish crosslinking between specific sites on adjoining strands of oligonucleotides or oligodeoxynucleotides. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel oligonucleotides for diagnostic and therapeutic purposes. The crosslinking agents of the invention are of the following formula (I'):

$$R_1—B—(CH_2)_q—(Y)_r—(CH_2)_m—A' \quad (I')$$

wherein,

R_1 is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3' or its 5' position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q_1 Q_2 and Q_3or with a reactive precursor thereof suitable for nucleotide bond formation;

Q_1 is hydroxy, phosphate or diphosphate;

Q_2 is =O or =S;

Q_3 is CH_2—R', S—R', O—R', or N—R'R";

each of R' and R" is independently hydrogen or C_{1-6} alkyl;

B is a nucleic acid base or analog thereof that is a component of an oligonucleotide;

Y is a functional linking group;

each of m and q is independently 0 to 8, inclusive;

r is 0 or 1; and

A' is a leaving group.

This invention is also directed to novel 3,4-disubstituted and 3,4,-trisubstituted pyrazolo[3,4-d]-pyrimidines and to the use of these nucleic acid bases in the preparation of oligonucleotides. The invention includes nucleosides and mono- and oligonucleotides comprising at least one of these pyrazolopyrimidines, and to the use of the resulting novel oligonucleotides for diagnostic purposes.

15 Claims, 3 Drawing Sheets